- Home
- KRRO
KRRO
Korro Bio Inc.
as 12-20-2024 4:00pm EST
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 490.1M | IPO Year: | 2019 |
| Target Price: | $133.83 | AVG Volume (30 days): | 132.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $30.01 - $98.00 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Korro Bio Inc. (KRRO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Agarwal Vineet | KRRO | Chief Financial Officer | Nov 11 '24 | Sell | $70.00 | 800 | $56,000.00 | 0 | |
| Agarwal Vineet | KRRO | Chief Financial Officer | Oct 17 '24 | Sell | $77.60 | 10,216 | $799,526.98 | 0 |
Latest Korro Bio Inc. News
KRRO Breaking Stock News: Dive into KRRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors
GlobeNewswire
a month ago
Korro to Participate in Upcoming Investor Conferences
GlobeNewswire
a month ago
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
GlobeNewswire
a month ago
Korro to Present at the Jefferies London Healthcare Conference
GlobeNewswire
a month ago
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
2 months ago
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
Investor's Business Daily
2 months ago
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
Investor's Business Daily
2 months ago
Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed.
Compare KRRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KRRO Korro Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.